Affimed reveals 25% of staff were laid off in April in wake of phase 2 lymphoma fail

April was a tricky month for Affimed. We already knew that a phase 2 fail prompted the end of plans to develop a bispecific antibody as a monotherapy in lymphoma. Now, Affimed has revealed that the resulting reorganization also meant a quarter of its employees were shown the exit.